Degradation behavior and biocompatibility of PEG/PANI-derived polyurethane co-polymers.

A series of polyurethane (PU) co-polymers with designable molecular weight between cross-linking dots was synthesized by a hydrogen transfer polymerization route from polyaniline (PANI), poly(ethylene glycol) (PEG), various curing agents and chain extenders using dibutyltin dilaurate as a catalyst. Their swelling, hydrophilicity, degradation and biocompatibility were inspected and assessed based on different degrees of polymerization of PANI and PEG, and their component proportion. Fourier transformation infrared spectrometry (FT-IR), (1)H-NMR spectroscopy, scanning electron microscopy (SEM), gel-permeation chromatography (GPC) and goniometry were used to characterize the structure and surface morphology of the synthesized PEG/PANI-based PU co-polymers, PU residues after degradation and degraded polymers at different time periods of hydrolysis. The thermal properties, aggregate structure and surface microstructure were examined by differential scanning calorimetry (DSC), wide-angle X-ray diffraction (WAXD) and atomic force microscopy (AFM). Hemolysis, static platelet adhesion, dynamic clotting measurements and MTT assays were adopted to evaluate the hemo- or cytocompatibility. The experimental results indicated that these polymers exhibit various degrees of micro-phase separation, depending on the concentration and degree of polymerization of PANI, molecular weight of PEG, type of curing agent and chain extender, which further influence their swelling, hydrophilicity, degradable properties and biological performances in vitro. The incorporation of PANI and PANI* in co-polymers led to decreased thermal stability but slower decomposition rates than typical PEG-based PUs. The stress-strain tests showed that the as-prepared PU co-polymers possessed increased tensile strength and modulus, and decreased toughness in comparison with the blank PEG-based PU. These co-polymers are expected to find specific applications in tissue engineering or controlled drug release.